Jci_page_head_homepage_01 Jci_page_head_homepage_02
Debanjan Chakroborty, Uttio Roy Chowdhury, Chandrani Sarkar, Rathindranath Baral, Partha Sarathi Dasgupta, Sujit Basu
Published in Volume 118, Issue 4
J Clin Invest. 2008; 118(4):1380–1389 doi:10.1172/JCI33125
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 6
Four-color flow cytometry showing presence of DA D2 receptors on EPCs; DA inhibits VEGFA-induced migration of EPCs in vitro.

(AC) Respective isotype controls. (D) After excluding dead cells and debris, total CD45 cells were gated (gate R2). (E) CD45cells were further analyzed for the presence of CD34 and VEGFR2. Upper-right quadrant represents CD45CD34+VEGFR2+ EPCs. These cells were further gated (gate R3) to analyze the presence of D2 receptors. (F) Histogram showing the presence of D2 receptors in 98% of the CD45CD34+VEGFR2+ EPCs. (G) Migration assay of cultured EPCs. DA was found to exert significant inhibition on VEGFA-induced migration of EPCs in a modified Boyden chamber. Treatment with eticlopride, a DA D2 receptor antagonist, prior to DA treatment, completely abrogated the inhibitory effect of DA. Figures are representative of 4 separate experiments for each group. *P < 0.05.